← All trials
NCT04602013
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2020
- Primary completion
- May 31, 2022
- Completion date
- May 31, 2022
- First posted
- Oct 26, 2020
- Last posted
- Oct 26, 2020
- Enrollment
- 53
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Electronic Science and Technology of ChinaLead sponsor
- Ningxia Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- China Three Gorges University, Yichang, ChinaCollaborator
- University of Electronic Science and Technology of ChinaReponsible party - principal investigator
- University of Electronic Science and Technology of ChinaStudy chair
- Southwest Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.